DSpace Arşivi :: by Yazar "Üyetürk, Ümmügül" değerine göre listeleniyor

Yazar "Üyetürk, Ümmügül" seçeneğine göre listele

Listeleniyor 1 - 20 / 44

Anaplastic thyroid carcinoma case series
(2024) Küçüköztaş, Nadire; Duman, Tuba Taslamacioğlu; Düzcü, Selma Erdoğan; Rahatli, Samed; Üyetürk, Ümmügül
Aim: Among the endocrine malignancies, thyroid carcinoma (TC) is the most common. However, anaplastic TC accounts for 1-2% of these cancers. The aim of this study was to evaluate the demographic and pathologic features, treatments, and survival of patients with anaplastic TC. Methods: Anaplastic TC patients who applied to our medical oncology clinics between 01.01.2012 -01.12.2018 were retrospectively evaluated. Results: A total of 8 patients were included in the study. There were 4 female and 4 male patients with a median age of 68 (minimum 61-maximum 83) years. The initial complaint of all patients was a fast-growing swelling in the neck. Six patients had total thyroidectomy. Two patients had anaplastic TC with a differential TC. Six patients were at stage 4C. The most common site of metastasis was the lung (75%). Five patients had received a median of 3 (1-6) cycles of chemotherapy. Radiotherapy was applied to 7 patients. All patients except one died during the follow-up period. The median survival time of the patients was 3 (2-15) months. Conclusion: Anaplastic TC, an aggressive tumor with high metastasic potential, has no effective treatment at present. Effective treatments are needed for this rare and aggressive disease. Developments in the molecular field are promising for the treatment of ATC.
Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a multicenter study of the Anatolian society of medical oncology
(Humana Press Inc, 2014) Üyetürk, Ümmügül; Öksüzoğlu, Berna; Akman, Tülay; Türker, İbrahim; Şener, Nur
Primary metastatic breast cancer (PMBC) comprises 3-10 % of all BCs. PMBC is a heterogeneous disease. To date, little is known about the tumor characteristics, treatment results, and overall survival ( OS) of patients with PMBC. Patients were considered to have PMBC if distant metastasis was evident within 3 months of the initial diagnosis of BC. Between September 2007 and April 2013, 466 PMBC patients were included in this study and analyzed retrospectively. The median age of the patients was 50 (18- 90) years. Bone/ soft tissue metastases were more frequent in the hormone receptor (HR)(+) human epidermal growth factor receptor ( HER) 2(-) group compared with the HR(-) HER2(-) and HR(-) HER2(-) groups ( p < 0.001), whereas visceral organ metastasis was more frequent in the HR(-) HER2(-) and HR(-) HER2(-) groups ( p < 0.001). The OS was affected by Eastern Cooperative Oncology Group performance status, tumor histology, receptor status, and the site of metastasis ( p < 0.001, p < 0.001, p < 0.001, and p = 0.011, respectively). According to the first-line systemic treatment choices of the patients, the longest median OS was observed in the HR(?) HER2(-) group who received hormonotherapy combined with trastuzumab after chemotherapy ( 86 months, 95 % CI 23.8-148.1) and the shortest median OS was observed in the HR(-) HER2(-) group who received chemotherapy only ( 24 months, 95 % CI 17.9-30.0) ( p < 0.001). Bisphosphonate therapy or radiotherapy had no significant effect on OS ( p = 0.733, 0.603). In multivariate analysis, hormonotherapy, chemotherapy + trastuzumab, trastuzumab + hormonotherapy following chemotherapy, and surgery were the most important prognostic factors for OS, respectively ( p < 0.001, p = 0.025, p = 0.027, p = 0.029). The general characteristics of the primary tumor are important for the prognosis and survival of patients with PMBC. Interestingly, patients who underwent primary breast tumor surgery, even those at the metastatic stage upon admission, had the longest survival.
Awareness of cancer screening during the treatment of renal failure patients : Physician questionnaire
(Oxford Univ Press, 2012) Sönmez, Özlem Uysal; Üyetürk, Ümmügül; Budakoğlu, Işıl İrem; Kazancıoğlu, Rümeyza; Türker, İbrahim; Budakoğlu, Burçin; Arslan, Ülkü Yalçıntaş
Awareness of cancer screening during treatment of patients with renal failure : a physician survey in Turkey
(Asian Pacific Organization Cancer Prevention, 2014) Uysal-Sönmez, Özlem; Tanrıverdi,Özgür; Üyetürk, Ümmügül; Budakoğlu, Işıl İrem; Kazancıoğlu, Rümeyza
Background: Today, survival rate of patients with chronic renal failure/hemodialysis has increased so that chronic illnesses are more likely to occur. Cancer is the main cause of morbidity and mortality in such patients. Aim: In this study, physician attitudes were examined about cancer screening in patients with renal failure. Materials and Methods: This study was done by face to face questionnaire in the 27th National Nephrology Congress to determine if the physicians dealing with chronic renal failure, hemodialysis or renal transplanted patients, recommend cancer screening or not and the methods of screening for cervix, prostate, breast and colon cancer. Results: One hundred and fifty six physicians were included in the survey. A total of 105 (67%) participants were male and the age of responders was 48 +/- 9 years. About 29% were specialists in nephrology, 28% internal medicine, and 5% were other areas of expertise. Some 48% of participants were hemodialysis certified general practitioners. Patients were grouped as compensated chronic renal failure, hemodialysis or renal transplanted. Of the 156 responders, 128 (82%) physicians recommended breast cancer screening and the most recommended subgroup was hemodialysis patients (15%). The most preferred methods of screening were combinations of mammography, self breast examination and physicianbreast examination. 112 (72%) physicians recommended cervix cancer screening, and the most preferred method of screening was pap-smear. Colon cancer screening was recommended by 102 (65%) physicians and prostate screening by 109 (70%) physicians. The most preferred methods of screening were fecal occult blood test and PSA plus rectal digital test, respectively. Conclusions: It is not obvious whether cancer screening in renal failure patients is different from the rest of society. There is a variety of screening methods. An answer can be found to these questions as a result of studies by a common follow-up protocol and cooperation of nephrologists and oncologists.
Bolu ilindeki testis kanserli hastaların retrospektif analizi
(2015) Üyetürk, Uğur; Üyetürk, Ümmügül; Metin, Ahmet
Amaç: Tests kanseri (Tca) erkeklerde görülen ürogenital malignitelerin yaklaşık %20’sini, tüm erkek maligni- telerinin yaklaşık %1-2’sini oluşturmasına rağmen, 15-35 yaş arası en sık görülen solid kanserlerdir. Kriptorşi- dizm, testküler mikrolitasis, Klinifelter ve Down Sendromu Tca için risk faktörleridir. Tca’lerinin %95’i germinal dokudan köken alır. Bu tümörler seminomatöz ve nonseminomatöz (embriyonel hücreli karsinom, teratom, koryokarsinom, yolk kesesi tümörü) olarak iki gruba ayrılmaktadır. Biz bu çalışmada, bölgemizde yaşayan Tca tanısı almış hastaların genel özelliklerini ve tedavi seçenekle rini retrospektf olarak değerlendirmeyi amaçladık. Gereç ve Yöntemler: 01.01.2012-30.07.2013 tarihleri arasında Bolu Abant İzzet Baysal Üniversitesi Tıp Fakülte - si, tbbi onkoloji polikliniğine başvuran Tca’li hastaların demografk özellikleri ve tedavi seçenekleri retrospektf olarak değerlendirildi. Bulgular: Bu süre içinde median yaşı 31(22-45) yıl olan 15 hastanın başvurduğu bulundu. İlk başvuru şikayet olarak 11’nunda (%74) testste kitle, 2’sinde (%13) ağrı, 2’sinde (%13) kitle ile birlikte ağrı vardı. Hastaların 14’ünde tümör unilateral, 1’inde bilateraldi. Tümör boyutu ortalama 4(0.8-10) cm’di. Hastaların tümörlerinin 7’si seminomatöz, 7’si nonseminomatöz ve bilateral tümörlü hastanın sağ testsi seminomatöz, diğeri nonse - minomatöz histolojiye sahipt. Orşiektomi sonrası seminomatöz evre IA olan 2 hastaya karboplatn, 1 hastaya izlem, evre IB olan 2 hastaya karboplatn, 1 hastaya izlem, evre IIB olan 1 hastaya bleomisin, etoposid, sisplatn (BEP) kemoterapisi verildiği, nonseminomatöz evre IA 2 hastaya izlem, evre II ve üzeri hastalara ise BEP kemoterapisi verildiği görüldü. Sonuç: Bolu ilindeki Tca’li hastaların değerlendirildiği bu retrospektf analiz sonuçları literatür ile uyumlu bulundu. Türkiye verilerini elde edebilmek için diğer illerinde dahil edileceği, daha fazla hasta katlımıyla yapılacak çalışmaların gerekli olduğunu düşünmekteyiz.
The clinical and pathological features of 133 colorectal cancer patients with brain metastasis: a multicenter retrospective analysis of the Gastrointestinal Tumors Working Committee of the Turkish Oncology Group (TOG)
(Humana Press Inc, 2014) Tanrıverdi, Özgür; Kaytan-Sağlam, Esra; Ülger, Şükran; Bayoğlu, İbrahim Vedat; Türker, İbrahim; Öztürk-Topçu, Türkan; Çokmert, Suna; Turhal, Serdal; Oktay, Esin; Karabulut, Bülent; Kılıç, Diclehan; Küçükzeybek, Yüksel; Öksüzoğlu, Berna; Meydan, Nezih; Kaya, Vildan; Akman, Tülay; İbiş, Kamuran; Sağnak, Mert; Şen, Cenk Ahmet; Uysal-Sönmez, Özlem; Pilancı, Kezban Nur; Demir, Gökhan; Sağlam, Sezer; Koçar, Muharrem; Menekşe, Serkan; Göksel, Gamze; Yapar-Taşköylü, Burcu; Yaren, Arzu; Üyetürk, Ümmügül
Brain metastasis in colorectal cancer is highly rare. In the present study, we aimed to determine the frequency of brain metastasis in colorectal cancer patients and to establish prognostic characteristics of colorectal cancer patients with brain metastasis. In this cross-sectional study, the medical files of colorectal cancer patients with brain metastases who were definitely diagnosed by histopathologically were retrospectively reviewed. Brain metastasis was detected in 2.7 % (n = 133) of 4,864 colorectal cancer patients. The majority of cases were male (53 %), older than 65 years (59 %), with rectum cancer (56 %), a poorly differentiated tumor (70 %); had adenocarcinoma histology (97 %), and metachronous metastasis (86 %); received chemotherapy at least once for metastatic disease before brain metastasis developed (72 %), had progression with lung metastasis before (51 %), and 26 % (n = 31) of patients with extracranial disease at time the diagnosis of brain metastasis had both lung and bone metastases. The mean follow-up duration was 51 months (range 5-92), and the mean survival was 25.8 months (95 % CI 20.4-29.3). Overall survival rates were 81 % in the first year, 42.3 % in the third year, and 15.7 % in the fifth year. In multiple variable analysis, the most important independent risk factor for overall survival was determined as the presence of lung metastasis (HR 1.43, 95 % CI 1.27-4.14; P = 0.012). Brain metastasis develops late in the period of colorectal cancer and prognosis in these patients is poor. However, early screening of brain metastases in patients with lung metastasis may improve survival outcomes with new treatment modalities.
Clinical outcomes and prognostic factors of adult's Ewing sarcoma family of tumors: single center experience
(Termedia Publishing House Ltd, 2016) Üyetürk, Ümmügül; Helvacı, Kaan; Demirci, Ayşe; Sönmez, Özlem Uysal; Türker, İbrahim
Aim of the study was to investigate the demographics of Ewing sarcoma family of tumours (ESTF) patients, treatment alternatives, clinical outcomes, and prognostic factors for survival. Material and methods: We retrospectively reviewed 39 patients with ESFT who were admitted to our institute between September 2008 and September 2012. Results: The patients included 32 (82.1%) males and seven (17.9%) females of median age 24 (range, 18-66) years. Among the 27 patients with a primary osseous localization, 17 (43.5%) had a central axis localization. Fifteen patients (38.5%) had metastases at the time of diagnosis. Patients were followed up for a median period of 18 (range, 2-134) months. The median event-free survival (EFS) was 23 (range, 1-64) months, and the 1- and 4-year EFS were 60% and 48%, respectively. The median overall survival (OS) was 91 (range, 1-188) months, and the 1- and 4-year OS were 78% and 54%, respectively. Gender, age, primary tumor site, and local treatment modalities, either alone or in combination, did not have a significant effect on OS (p = 0.210, p = 0.617, p = 0.644, and p = 0.417, respectively). In contrast, osseous site of peripheral localization, limited stage, and metastasis to the bone significantly affected OS (p = 0.015, p < 0.001, and p = 0.042, respectively). Conclusions: ESFTs are aggressive tumors with a high rate of relapse and metastatic potential. Patients with peripheral bone involvement and limited stage had a good prognosis. Appropriate surgical resection, radiotherapy, and aggressive chemotherapy regimens are recommended.
Comparison of the effect of filgrastim vs. lenograstim started during febrile neutropenia attack in patients with solid tumors
(Elsevier Sci Ltd, 2013) Sönmez, Özlem Uysal; Güçlü, Ertuğrul; Türker, İbrahim; Üyetürk, Ümmügül; Bal, Öznur
Demographic features and factors affecting overall survival in patients with hepatocellular carcinoma : A retrospective analysis in Turkey
(Carbone Editore, 2013) Üyetürk, Ümmügül; Köş, Fahriye Tuğba; Helvacı, Kaan; Sönmez, Özlem Uysal; Türker, İbrahim; Aktaş, Gülali
Objective: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. Cirrhosis, due to hepatitis B virus (HBV) or hepatitis C virus (HCV), and alcohol is the most important risk factor for HCC. In this analysis, we evaluated demographic characteristics, risk factors, prognostic factors, and overall survival (OS) of patients with HCC. Methods: Data from patients with HCC, who presented at medical oncology outpatient clinics of three centers between April 2007 and April 2012, were assessed retrospectively. Patient demographics, treatments, progression, and the date of last follow-up were recorded. Results: This analysis included 166 patients [138 males (83.1%), 28 (16.9%) females] with a mean age of 62 (range, 18-86) years. Ninety-two (55%) patients were followed for cirrhosis before HCC was diagnosed. HBV positivity, HCV positivity, and a history of alcohol consumption were present in 102 (61.4%), 16 (9.6%), and 50 (30.1%) patients, respectively. Distant metastasis occurred in 34 (20.5%) patients. Multivariate analysis showed that the most significant prognostic factors for OS were a history of alcohol consumption (p = 0.002), Eastern Cooperative Oncology Group performance status (p < 0.001), Child-Pugh score (p = 0.005), transplantation (p = 0.049), and transarterial chemoembolization (p < 0.001). Discussion: We found that long survival could be achieved by the provision of local treatment modalities to patients with early-stage HCC and good performance status. Vaccination against HBV, which plays a major role in the etiology of HCC, should be prioritized and efforts should be made to detect HCC in the early stages.
Dermatofibrosarcoma protuberans: A rare malignancy
(2017) Üyetürk, Ümmügül; Duman, Tuba Taslamacıoğlu; Düzcü, Selma Erdoğan; Küçüköztaş, Nadire; Yılmaz, Fahri
OBJECTIVE Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by protuberant growth pattern of skin and subcutaneous tissue. The annual incidence is 4.2 per million. It is often seen between the ages of 20–50 years. This study aimed to evaluate the characteristics of patients with DFSP. METHODS Patients who visited our clinic were retrospectively evaluated. RESULTS All patients were females and the median age was 42 (29–60) years. The evaluated tumor sites were observed in the body/trunk in one patient, at the hip in two, and at the proximal lower extremity in two. Sur gical excision was done in all of them as initial treatment. Re-excision was needed in three patients. One of the patients underwent punch biopsy for diagnosis and surgical removal of the tumor with a negative surgical margin. One of the patients underwent radiotherapy. The median follow-up time was 10 (6–26) months. During the median follow-up, there was no local recurrence or metastasis. CONCLUSION As initial treatment, it is important to surgically remove tumors that had no distant metastasis. Positive or near surgical margins should be resected again. If a negative surgical margin cannot be achieved, radiotherapy should be used as the treatment. Imatinib mesylate is used for treatment in unresectable, recurrent, and/or metastatic tumors.
Dermatofibrosarcoma protuberans: a rare malignancy
(Kare Publ, 2017) Üyetürk, Ümmügül; Duman, Tuba Taslamacıoğlu; Düzcü, Selma Erdoğan; Küçüköztaş, Nadire; Yılmaz, Fahri
OBJECTIVE Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by protuberant growth pattern of skin and subcutaneous tissue. The annual incidence is 4.2 per million. It is often seen between the ages of 20-50 years. This study aimed to evaluate the characteristics of patients with DFSP. METHODS Patients who visited our clinic were retrospectively evaluated. RESULTS All patients were females and the median age was 42 (29-60) years. The evaluated tumor sites were observed in the body/trunk in one patient, at the hip in two, and at the proximal lower extremity in two. Surgical excision was done in all of them as initial treatment. Re-excision was needed in three patients. One of the patients underwent punch biopsy for diagnosis and surgical removal of the tumor with a negative surgical margin. One of the patients underwent radiotherapy. The median follow-up time was 10 (6-26) months. During the median follow-up, there was no local recurrence or metastasis. CONCLUSION As initial treatment, it is important to surgically remove tumors that had no distant metastasis. Positive or near surgical margins should be resected again. If a negative surgical margin cannot be achieved, radiotherapy should be used as the treatment. Imatinib mesylate is used for treatment in unresectable, recurrent, and/or metastatic tumors.
Diffuse gastric mantle cell lymphoma resembling gastrointestinal stromal tumors
(Mosby Inc., 2014) Yılmaz, Bülent; Poşul, Emrah; Çöl, Cavit; Üyetürk, Ümmügül; Boran, Çetin; Aktaş, Gülan; Kurt, Mevlüt
An 81-year-old man was admitted to our gastroenterology unit because of anemia. He had experienced anorexia, nausea, fatigue, and weight loss (6 kg) during the past 4 months. The results of physical examination were unremarkable; there was no lymphadenopathy, hepatosplenomegaly, or palpable abdominal mass.
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish oncology group study
(Imprimatur Publications, 2020) Yıldız, Birol; Küçükarda, Ahmet; Gökyer, Ali; Demiray, Atike Gökçen; Paydaş, Semra; Aral, İpek Pinar; Gümüşay, Özge; Üyetürk, Ümmügül
Purpose: The purpose of this study was to determine whether primary tumor localization may be a risk factor for relapse and survival in seminomatous germ cell tumors (GCT) patients. Methods: In our study, 612 seminomatous GCT patients diagnosed in 22 centers between 01.01.1989 and 03.02.2019 were retrospectively evaluated. Patient interview information, patient files and electronic system data were used for the study. Results: The primary tumor was localized in the right testis in 305 (49.9%) patients and in 307 (50.1%) in the left testis. Mean age of the patients was 36 years (range 16-85 +/- 10.4). The median follow-up period was 47 months (1-298). Recurrence was observed in 78 (127%) patients and 29 (4.7%) died during the follow-up period. Four-year overall survival (OS) was 95.4% and 4-year progression-free survival (PFS) was 84.5%. The relationship between localization and relapse was significant in 197 patients with stage 2 and stage 3 (p=0.003). In this patient group, 41 (20.8%) relapses were observed. Thirty (73.2%) of the relapses were in the right testis and 11 (26.8%) in the left testis. Four-year OS was 92.1% in patients with right tumor; and 98.7% in patients with left tumor (p=0.007). When 612 patients were evaluated with a mean follow-up of 4 years, there was a 6.6% survival advantage in patients with left testicular tumor and this difference was significant (p=0.007). Conclusion: Survival rates of patients with primary right testicular localization were worse compared with left testicular localization, and relapse rates were higher in stage 2 and 3 patients with right testicular localization.
Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?
(Sage Publications Inc, 2015) Tekçe, Buket Kin; Üyetürk, Ümmügül; Tekçe, Hikmet; Üyetürk, Uğur; Aktaş, Gülali; Akkaya, Akcan
Background It is not possible to diagnose acute kidney injury (AKI) in early stages with traditional biomarkers. Kidney injury molecule-1 (KIM-1) is a novel biomarker promising the diagnosis of AKI in early stages. We studied whether urinary and serum KIM-1 (KIM-1(U) and KIM-1(S)) concentrations were useful in predicting cisplatin-induced AKI in early stages. Methods We prospectively analysed 22 patients on cisplatin treatment. KIM-1(S) and KIM-1(U) concentrations were assessed in the samples of the patients on four different time periods (before treatment [BT], first [AT(1)], third [AT(3)] and fifth [AT(5)] day after treatment). Results KIM-1(U) concentrations on the first day after cisplatin treatment in patients with AKI were significantly increased compared to both KIM-1(U) concentrations of the same patients BT (P=0.009) and to AT(1)-KIM-1(U) concentrations of the patients without AKI (P=0.008). A receiver operating characteristic analysis revealed that AT(1)-KIM-1(U) concentrations may predict AKI with an 87.5% sensitivity and 93.3% specificity (area under the curve=0.94). KIM-1(S) concentrations were not significantly changed between BT and AT periods. Conclusions KIM-1(U) concentrations may predict cisplatin-induced AKI in early stages with high sensitivity and specificity.
Effect of direct education on breast self examination awareness and practice among women in Bolu, Turkey
(Asian Pacific Organization Cancer Prevention, 2013) Gücük, Sebahat; Üyetürk, Ümmügül
Aims: To evaluate breast self examination (BSE) practice and the effect of a training program conducted by healthcare professionals on BSE. Materials and Methods: Women were randomized into control and test groups with both groups completing a questionnaire and three independent interviews where their BSE practices were evaluated. Results: In all, 39.5% of the participants were previously provided information on BSE by healthcare professionals while 25.8% had no knowledge of BSE prior to enrollment. Compared to those informed about BSE through other means such as television, radio, and the internet, the scores of the first, second, and third visits were higher (p<0.05) in individuals who received BSE education from healthcare professionals and hospitals. Conclusions: BSE training provided by healthcare professionals may increase early breast cancer diagnosis and treatment rates by improving BSE awareness and practice.
The effects of hypericin on ADAMTS and p53 gene expression in MCF-7 breast cancer cells
(Imprimatur Publications, 2014) Acar, Muradiye; Ocak, Zeynep; Erdoğan, Kübra; Çetin, Elif Nihan; Hatipoğlu, Ömer Faruk; Üyetürk, Ümmügül
Purpose: The purpose of this study was to determine the effects of hypericin on MCF-7 (Michigan Cancer Foundation-7) breast cancer cells, as it is known to exert an antitumor effect on the expression and regulation of ADAMTS1, 3, 10 and the p53 gene in breast cancer cells. Methods: MFC-7 cells were cultured and subjected separately to various doses (1, 5 and 7.5 mu g/mL) hypericin. After 24 hrs, RNA was isolated and transcribed into cDNA. Expression analysis was performed by real time (RT)-PCR and cell survival was determined by the XTT assay. Results: While the expression of ADAMTS1 in MFC-7 cells decreased to 0.04-fold after exposure to 1 mu g/mL hypericin, the expression increased by 5.6- and 36-fold with 5 and 7.5 mu g/mL, respectively. Furthermore, ADAMTS3 expression in MCF7 cells increased 3.9-fold with the use of 5 mu g/mL of hypericin. These concentrations of hypericin did not lead to significant changes in the expression of ADAMTS10 and the p53 gene. Viability of cancer cells as evaluated by the XTT assay showed that hypericin concentration of 7.5 mu g/mL led to increased apoptosis of cancer cells. Conclusion: The increase in ADAMTS1 expression may prevent metastasis or facilitate the development of an adjuvant factor with tumor-suppressive effects. Hypericin may therefore exert its antitumor and apoptotic effects in MFC-7 cells via ADAMTS1 and ADAMTS3.
Efficacy and toxicity of cisplatin and capecitabine combination in the first-line treatment of patients with advanced gastric cancer: A multicenter study by the Anatolian Society of Medical Oncology
(2016) Çiltaş, Aydın; Büyükberber, Süleyman; Topcu, Turkan O.; Küçüköner, Mehmet; Üyetürk, Ümmügül
Gastric cancer is an important public health problem which comprises 10% of all cancers and 12% of all cancer related deaths all over the world. Because of the differences in patient populations and treatment schemes in various studies, standard practice for advanced stage gastric cancer has not been fully established. The aim of this study was to assess the use of cisplatin and capecitabine combination regimen in real-world clinical practice. Medical records of 76 male and 37 female metastatic gastric cancer patients treated with first-line cisplatin and capecitabine combination between February 2006 and December 2009 were retrospectively analyzed in 11 centers of the Anatolian Society of Medical Oncology. Patients previously treated with chemotherapy were excluded from the analysis. The median age of the patients was 64 years . Seventy-six (67.2%) patients were males and 37 (32.7%) females. Most of the patients were metastatic (n= 85, 75.2%) at the time of initial diagnosis. The most common sites for metastasis were liver (65.9%), lung (11.3%), peritoneum (23.8%) and local recurrence (15.9%) with multiple metastases in 9.7% of the patients. The mean follow-up period of all patients was 41 months . Overall response rates was 33.6%, while disease control rate (DCR) was 72.6 %. Median Progression-free survival was 4.7 months (95%CI 3.75- 6.49) and median overall survival was 11.1 months (95%CI 5.58- 10.98). The most common grade 3-4 adverse events were anemia (8.3%), nausea-vomiting (3.8%) and diarrhea (1.8%). In terms of efficacy, toxicity and convenience, cisplatin and capecitabine combination is effective and well tolerated in Turkish patients with advanced gastric cancer, and could be one of the standard regimens for the first-line treatment in this cohort.
Evaluation Of Demographic And Clinicopathological Characteristics Of Panreatic Adenocarcinoma Patients
(2016) Helvacı, Kaan; Üyetürk, Ümmügül; Sönmez, Özlem; Türker, İbrahim; Yalçıntaş, Ülkü Arslan
AMAÇ: Pankreas kanserleri hastalarının tanı anında sadece %15-20'si cerrahi olarak çıkarılabilir aşamada olup %52'sinde yaygın hastalık %26'sında bölgesel yayılım mevcuttur (1). Pankreas kanserinin bir yıllık genel sağ kalım oranı %26, beş yıllık ise % 6'dır (2). Bu çalışmanın amacı Türkiye'de merkezi bir bölgede bulunan ve referans merkez olarak kabul edilen Ankara Onkoloji Eğitim Araştırma Hastanesi'ne başvuran pankreas adenokanserli hastaların klinikopatolojik özelliklerinin incelenmesidir. GEREÇ VE YÖNTEM: Çalışma için Ankara Onkoloji Eğitim ve Araştırma Hastanesi'nde 2007-2011 tarihleri arasında izlenmiş 121 erkek ve 72 kadından oluşan toplam 193 pankreas adenokanseri hastası retrospektif olarak tarandı. BULGULAR: Hastaların 26'sına (%13,5) küratif rezeksiyon uygulanmıştı, 54 hasta (%28) lokal ileri çıkarılamaz, 113 hasta ise (%58,5) metastatik evredeydi. Tüm grup için (n=193) ortanca sağ kalım süresi 6 ay olarak bulundu. Yaşın, ortanca yaş olan 61 den büyük olması, ECOG performans durumunun 3 ve üzerinde değer olması, başlangıçta kilo kaybı olması, başlangıçta karın ağrısı olması, tümör gradının yüksek olması, tümörün lokal ileri veya metastatik olması, başlangıç metastaz bölgesinin periton veya karaciğer dışı olması, başlangıçta çoklu metastaza sahip olunması sağ kalıma anlamlı olumsuz yönde etkilemekteydi. Küratif opere edilen hastalar dışlanarak çıkarılamaz ve metastatik hastalar için bakılan CA19-9 değerinin ortanca değer olan 616'nın üzerinde olması kötü sağ kalım ile ilişkili idi (p=0,021). Metastatik aşamada kemoterapi almış olmak en iyi destek tedavisine bariz olarak üstündü. Ortanca sağ kalım kemoterapi almayan kol için 1 ay (0,2-1,7) iken almış olan kolda 7 (4,7-9,3) ay idi (p<0,0001). Lokal ileri çıkarılamaz grupta ise bu fark gösterilemedi. SONUÇ: Hastaların klinik ve demografik incelenmesi neticesinde daha önceden yapılmış çalışmalarla genellikle benzer sonuçlara ulaşılmıştır. Hastalardaki ortanca yaşın dünya ortancasına göre düşük olması, Türkiye'de sigaraya başlama yaşının daha erken olması ile ilişkili olabileceğini akla getirmektedir. Tedavi kararı verirken yaş durumundan çok performans durumuna ve evresine göre karar vermek akıllıca olacaktır.
Evaluation of general characteristics of renal cell carcinoma patients: A single center experience
(2018) Üyetürk, Ümmügül; Duman, Tuba Taslamacıoğlu; Yılmaz, Burak; Küçüköztaş, Nadire; Üyetürk, Uğur
Objective: Renal cancer (RC) accounts for 3.2% of all newly diagnosed cancers and approximately 90% of RC cases are renal cell carcinoma (RCC). Smoking and hypertension are the most important risk factors. The aim of our study was to evaluate the general characteristics of RCC patients in Bolu, Turkey. Materials and Methods: Patients who visited our medical oncology clinic and were diagnosed with RCC between January 1st, 2012 and May 31st, 2017 were evaluated retrospectively. Results: Eighty-one patients were diagnosed with RCC during the study period. The median age of the patients was 62 years (range: 38-87 years). Fifty-seven (70.4%) of the patients were male and 24 (29.6%) were female. Thirty patients (37.1%) were diagnosed incidentally. Forty-eight (59.3%) of the patients were smokers. The most common comorbidity was hypertension (58%). Radical nephrectomy was performed in 59 (72.8%) of the patients. The most common histological subtype was clear cell carcinoma (72.8%) and 39 (48.1%) were stage 1 when evaluated according to the stage of RCC. Of the 16 patients with metastatic disease, 11 (13.6%) received interferon therapy, and 5 patients (6.2%) refused treatment. After interferon treatment, 7 patients received targeted therapy with sunitinib/pazopanib as second-line treatment, 5 received everolimus as third-line treatment, and 3 received axitinib treatment as fourth-line treatment. Ten patients with bone metastasis underwent palliative radiotherapy. The median follow-up time of the patients was 21 months (0-123 months). Sixty-five patients (80.2%) survived this period. Conclusion: Smoking cessation and effective treatment of hypertension, preventable etiological factors of RCC, and incidental diagnosis of early RCC are very important. With early diagnosis, the partial nephrectomy rate might be increased.
Evaluation of general features of patients with testicular cancer
(2020) Gülseven, Merve Erol; Üyetürk, Ümmügül; Geredeli, Çağlayan
Objective: Testicular cancers (Tca) are most common in men aged 20-34. Despite the increase in its incidence, the mortality rate from Tca decreases. In our study, it was aimed to evaluate the general characteristics, the treatments and survival of the patients who were followed up and treated with the diagnosis of Tca. Materials and Methods: In this study, patients who were admitted to Okmeydanı Training and Research Hospital and Abant İzzet Baysal University, Medical Faculty, Medical Oncology Outpatient Clinic between January 2004 and December 2014 with the diagnosis of Tca, were evaluated retrospectively. Results: In 324 (96.7%) of 332 patients included in the study with the diagnosis of Tca, testicular germ cell tumor (TGCT) was present. Of the patients, 150 (46.3%) had seminoma and 174 (53.7%) had non-seminoma tumors. The median age of patients with TGCT was 32 (minimum 18-maximum 81) years. Non-seminoma group was diagnosed at a younger age (p<0.05). The most common histology in the non-seminoma group was mixed germ cell tumor which was found in 135 patients (77.6%). The stage in which the patients were most diagnosed was stage I (seminoma 73.3% and non-seminoma tumor 44.3%, p<0.001). Distant metastasis was present in 3.5% of patients with seminoma and 32.7% of patients with non seminoma tumor (p<0.001). It was observed that 98% of the patients in the seminoma group and 85.6% of the patients in the non-seminoma group were in the good prognostic group (p<0.001). Radiotherapy, which was applied in 90 (81.8%) patients, was the most applied treatment in the group with stage I seminoma. In stage I non-seminomatous group, the most common treatment was cisplatin-based combination treatments, which was given to 58 (75.3%) patients. The median follow-up period of patients with stage I seminoma was 60 (minimum 3-maximum 134) months, and the median follow-up period of patients with non-seminoma tumor was 69 (minimum 8-maximum 178) months. Three hundred twelve (96.3%) patients with TGCT survived and 145 (96.7%) in the seminoma group and 167 (96%) patients in the non-seminoma group survived (p>0.05). Conclusion: The majority of our patients were diagnosed at an early stage and were in the good prognostic group. Most of our patients survived during our followup period.

Yazar "Üyetürk, Ümmügül" seçeneğine göre listele

Sayfa Başına Sonuç

Sıralama seçenekleri